Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 1.00 |
| ▸ | SLC5A1 | P13866 | 3/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.71 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13278337 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL27655347 | 0.90 | SLC5A2 (0.82) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL146555 | 0.88 | SLC5A2 (0.79) | SLC5A2SLC5A1 | |
| SCHEMBL22330742 | 0.88 | SLC5A2 (0.79) | SLC5A2SLC5A1 | |
| SCHEMBL203128 | 0.88 | SLC5A2 (0.79) | SLC5A2SLC5A1 | |
| SCHEMBL13192453 | 0.88 | SLC5A2 (0.79) | SLC5A2SLC5A1 | |
| SCHEMBL1585481 | 0.88 | SLC5A2 (0.79) | SLC5A2SLC5A1 | |
| SCHEMBL153045 | 0.87 | SLC5A2 (0.78) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL17627815 | 0.87 | SLC5A2 (0.77) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL28404062 | 0.86 | SLC5A2 (0.83) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104109155-A | Novel compounds | TANABE SEIYAKU CO | 2014-10-22 | — | — | CN | claimed |
| CN-103819465-A | Novel compound | MITSUBISHI TANABE PHARMA CORP | 2014-05-28 | — | — | CN | claimed |
| CN-103214471-A | Novel compound | MITSUBISHI TANABE PHARMA CORP | 2013-07-24 | — | — | CN | claimed |
| CN-1829729-A | Novel compounds | TANABE SEIYAKU CO (JP) | 2006-09-06 | — | — | CN | claimed |
| EP-1651658-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | TANABE SEIYAKU CO., LTD. (JP) | 2006-05-03 | — | — | EP | claimed |
| US-20050233988-A1 | Novel compounds | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-20 | — | — | US | claimed |
| WO-2005012326-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | TANABE SEIYAKU CO., LTD. (JP) | 2005-02-10 | — | — | WO | claimed |
| US-11576894-B2 | Combination therapy for the treatment of diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-14 | — | — | US | disclosed |
| EP-2455374-B1 | Process for the Preparation of Compounds useful as inhibitors of SGLT | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-16 | — | — | EP | disclosed |
| EP-3251679-B1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-12-16 | — | — | EP | disclosed |
| EP-2896397-B2 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-10-07 | — | — | EP | disclosed |
| EP-1651658-B2 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-08-12 | — | — | EP | disclosed |
| US-10544135-B2 | Process for the preparation of compounds useful as inhibitors of SGLT2 | JANSSEN PHARMACEUTICA NV (BE) | 2020-01-28 | — | — | US | disclosed |
| US-20100099883-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-22 | — | — | US | disclosed |
| US-20090233874-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | Tanabe Pharma Corporation (JP) | 2009-09-17 | — | — | US | disclosed |
| WO-2009035969-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | WO | disclosed |
| CN-1829729-A | Novel compounds | TANABE SEIYAKU CO (JP) | 2006-09-06 | — | — | CN | disclosed |
| EP-1651658-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | TANABE SEIYAKU CO., LTD. (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-20050233988-A1 | Novel compounds | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-20 | — | — | US | disclosed |
| WO-2005012326-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | TANABE SEIYAKU CO., LTD. (JP) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050233988-A1 | Novel compounds | CYP1B1, CYP4B1, CYP2B6 | SLC5A2 472/4885SLC5A1 303/4885ABCB11 24/4885 |
| US-20100099883-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | SLC5A1, SLC5A2, SI | SLC5A2 2/4885SLC5A1 1/4885ABCB11 263/4885 |
| US-20090233874-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | SLC5A1, SLC5A2, SI | SLC5A2 2/4885SLC5A1 1/4885ABCB11 263/4885 |
| US-10544135-B2 | Process for the preparation of compounds useful as inhibitors of SGLT2 | SLC5A2, SLC5A1, SI | SLC5A2 1/4885SLC5A1 2/4885ABCB11 286/4885 |
| US-11576894-B2 | Combination therapy for the treatment of diabetes | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885ABCB11 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.